Clinical use of a fixed-dose combination of telmisartan and indapamide in hypertension. Expert Council resolution
A. O. Konradi,
F. T. Ageyev,
A. S. Galyavich,
Yu. A. Karpov,
Zh. D. Kobalava,
Yu. V. Kotovskaya,
S. V. Nedogoda,
A. O. Nedoshivin,
O. N. Tkacheva https://doi.org/10.15829/1560-4071-2025-6249
EDN: RAPVSZ
Abstract
The aim of the expert council "First star duo of telmisartan and indapamide in the Russian Federation", dedicated to the introduction of a new fixed-dose combination of telmisartan and indapamide (modified-release tablets) into clinical practice was to formulate an expert opinion on the potential use of novel fixed-dose combination of telmisartan and indapamide in the treatment of hypertensive patients.
Supporting agencies: The resolution was supported by KRKA.
About the Authors
A. O. Konradi
"Национальный медицинский исследовательский центр им. В.А. Алмазова" Минздрава России
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
F. T. Ageyev
ФГБУ НМИЦ кардиологии им. акад. Е.И. Чазова Минздрава России
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
A. S. Galyavich
ФГБОУ ВО Казанский государственный медицинский университет Минздрава России
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
Yu. A. Karpov
ФГБУ НМИЦ кардиологии им. акад. Е.И. Чазова Минздрава России
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
Zh. D. Kobalava
Российский университет дружбы народов им. Патриса Лумумбы
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
Yu. V. Kotovskaya
ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Минздрава России (Пироговский университет) — ОСП Российский геронтологический научно-клинический центр
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
S. V. Nedogoda
ФГБОУ ВО Волгоградский государственный медицинский университет Минздрава России
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
A. O. Nedoshivin
ФГБУ "Национальный медицинский исследовательский центр им. В.А. Алмазова" Минздрава России
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
O. N. Tkacheva
ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
None
References
1. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) doi:10.15829/1560-4071-2024-6117. EDN GUEWLU.
2. Mancia G, Kreutz R, Brunström M, et al. ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480.
3. Chen R, Suchard MA, Krumholz HM, et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension. 2021;78(3):591-603. doi:10.1161/HYPERTENSIONAHA.120.16667.
4. Larsson SC, Markus HS. Does Treating Vascular Risk Factors Prevent Dementia and Alzheimer's Disease? A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2018;64(2):657-68. doi:10.3233/JAD-180288.
5. Adesuyan M, Jani YH, Alsugeir D, et al. Antihypertensive Agents and Incident Alzheimer's Disease: A Systematic Review and Meta-Analysis of Observational Studies. J Prev Alzheimers Dis. 2022;9(4):715-24. doi:10.14283/jpad.2022.77.
6. Hu W, Li Y, Zhao Y, et al. Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype. Front Aging Neurosci. 2020;12:154. doi:10.3389/fnagi.2020.00154.
7. Zhang P, Hou Y, Tu W, et al. Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans. Alzheimers Dement. 2023;19(5):1876-87. doi:10.1002/alz.12819.
8. Wu J, Wang M, Guo M, et al. Angiotensin Receptor Blocker is Associated with a Lower Fracture Risk: An Updated Systematic Review and Meta-Analysis. Int J Clin Pract. 2022;2022:7581110. doi:10.1155/2022/7581110.
9. Galzerano D, Capogrosso C, Di Michele S, et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010;6:113-33. doi:10.2147/vhrm.s7857.
10. Ayza MA, Zewdie KA, Tesfaye BA, et al. Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity. Diabetes Metab Syndr Obes. 2020;13:3627-35. doi:10.2147/DMSO.S265399.
11. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
12. Ernst ME, Fravel MA. Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide. Am J Hypertens. 2022;35(7):573-86. doi:10.1093/ajh/hpac048.
13. DiNicolantonio JJ, Bhutani J, Lavie CJ, O'Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Future Cardiol. 2015;11(2):203-17. doi:10.2217/fca.14.83.
14. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. Journal of Hypertension. 2000;18(10):1465-75.
15. Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* study. Journal of Hypertension. 2004;22(8):1613-22. doi:10.1097/01.hjh.0000133733.32125.09.
16. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens. 2006;19(1):113-21. doi:10.1016/j.amjhyper.2005.06.027.
17. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5.
18. Chalmers J, Mourad JJ, Brzozowska-Villatte R, et al. Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials. J Hypertens. 2023;41(3):508-15. doi:10.1097/HJH.000000000000336.
19. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98. doi:10.1056/NEJMoa08013.
Review
For citations:
Konradi A.O., Ageyev F.T., Galyavich A.S., Karpov Yu.A., Kobalava Zh.D., Kotovskaya Yu.V., Nedogoda S.V., Nedoshivin A.O., Tkacheva O.N. Clinical use of a fixed-dose combination of telmisartan and indapamide in hypertension. Expert Council resolution. Russian Journal of Cardiology. 2025;30(1):6249. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6249. EDN: RAPVSZ
Views:
1632
Email this article 